Evidence map›Paper›PMID 32085544›Full record

ArticleCancers2020

Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study.

Manuela Tiako Meyo, Anne Jouinot, Etienne Giroux-Leprieur, Elizabeth Fabre, Marie Wislez, Marco Alifano, Karen Leroy, Pascaline Boudou-Rouquette, Camille Tlemsani, Nihel Khoudour and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed, 10 pooled it
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

82 citing papers in PubMed, 10 syntheses or guidelines pooled it, 112 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. The prognostic value of methylated ctDNA, soluble PD-L1, and NK-cell activity on the risk of relapse after curative radiotherapy of non-small cell lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

22 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 3 institutions in 1 country.

Manuela Tiako MeyoDrug Biology-Toxicology, Cochin Hospital, AP-HP, CARPEM, 75014 Paris, France.
Anne JouinotDepartment of Medical Oncology, Cochin Hospital, AP-HP, Paris Descartes University, CARPEM, 75014 Paris, France.
Etienne Giroux-LeprieurDepartment of Respiratory Diseases and Thoracic Oncology, APHP-AmbroiseParé Hospital and EA 4340 University Versailles-Saint Quentin en Yvelines, 92100 Boulogne, France.
Elizabeth FabreDepartment of Thoracic Oncology, Georges Pompidou European Hospital, AP-HP, 75015 Paris, France.
Marie WislezDepartment of Pneumology, Cochin Hospital, APHP, 75014 Paris, France.ORCID 0000-0001-7518-7859
Marco AlifanoDepartment of Thoracic Surgery, Cochin Hospital, APHP, 75014 Paris, France.ORCID 0000-0002-2038-1037
Karen LeroyDepartment of Cyto-pathology, Cochin Hospital, AP-HP, 75014 Paris, France.
Pascaline Boudou-RouquetteDepartment of Medical Oncology, Cochin Hospital, AP-HP, Paris Descartes University, CARPEM, 75014 Paris, France.
Camille TlemsaniDepartment of Medical Oncology, Cochin Hospital, AP-HP, Paris Descartes University, CARPEM, 75014 Paris, France.ORCID 0000-0002-3342-1704
Nihel KhoudourDrug Biology-Toxicology, Cochin Hospital, AP-HP, CARPEM, 75014 Paris, France.
Jennifer ArrondeauDepartment of Medical Oncology, Cochin Hospital, AP-HP, Paris Descartes University, CARPEM, 75014 Paris, France.
Audrey Thomas-SchoemannUMR8038 CNRS, U1268 INSERM, Faculty of Pharmacy, Paris Descartes University, PRES Sorbonne Paris Cité, 75006 Paris, France.
Hélène BlonsDepartment of Cyto-pathology, Georges Pompidou European Hospital, AP-HP, 75015 Paris, France.
Audrey Mansuet-LupoDepartment of Cyto-pathology, Cochin Hospital, AP-HP, 75014 Paris, France.
Diane DamotteDepartment of Cyto-pathology, Cochin Hospital, AP-HP, 75014 Paris, France.
Michel VidalDrug Biology-Toxicology, Cochin Hospital, AP-HP, CARPEM, 75014 Paris, France.
François GoldwasserDepartment of Medical Oncology, Cochin Hospital, AP-HP, Paris Descartes University, CARPEM, 75014 Paris, France.
Jérôme AlexandreDepartment of Medical Oncology, Cochin Hospital, AP-HP, Paris Descartes University, CARPEM, 75014 Paris, France.
Benoit BlanchetDrug Biology-Toxicology, Cochin Hospital, AP-HP, CARPEM, 75014 Paris, France.
Délégation Paris 5 · FRHôpital Cochin · FRAssistance Publique – Hôpitaux de Paris · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A large interindividual variability has been observed in anti Programmed cell Death 1 (anti-PD1) therapies efficacy. The aim of this study is to assess the correlation of soluble PD-1 (sPD-1), soluble Programmed cell Death Ligand 1 (sPD-L1), Vascular Endothelial Growth Factor A (VEGFA), soluble CD40 ligand (sCD40L) and soluble CD44 (sCD44), with survival in nivolumab-treated metastatic non-small cell lung cancer (NSCLC) patients. Plasma biomarkers were assayed at baseline and after two cycles of nivolumab. A cut-off of positivity for sPD-1, sPD-L1 and sCD40L expressions was defined as a plasma level above the lower limit of quantification. Baseline sPD-1 and sPD-L1 levels were subsequently analyzed in a control group of

Indexed as

biomarkersImmune checkpoint inhibitorsnivolumabNSCLCPD-1

Identifiers

PMID32085544
PMCPMC7072584
OpenAlexW3007964415

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.